Orchestra BioMed Holdings Inc. Net Assets
Orchestra BioMed Holdings Inc. net assets. Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) has net assets worth $29.42 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($115.70 Million) and total liabilities ($86.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore OBIO net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $29.42 Million |
| % of Total Assets | 25.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 58.89 |
Net Assets of Orchestra BioMed Holdings Inc. (2020–2025)
Net assets of Orchestra BioMed Holdings Inc. from 2020 to 2025. This chart illustrates how Orchestra BioMed Holdings Inc.'s net assets have evolved over time, based on quarterly financial data. See Orchestra BioMed Holdings Inc. (OBIO) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Orchestra BioMed Holdings Inc. (2020–2025)
The table below shows the annual net assets of Orchestra BioMed Holdings Inc. from 2020 to 2025. For live market cap and overall valuation, see OBIO stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $63.38 Million | +92.30% |
| 2024-12-31 | $32.96 Million | -51.56% |
| 2023-12-31 | $68.04 Million | +29.52% |
| 2022-12-31 | $52.53 Million | +173.75% |
| 2021-12-31 | $-71.23 Million | -46.74% |
| 2020-12-31 | $-48.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Orchestra BioMed Holdings Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21946700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Orchestra BioMed Holdings Inc. Net Assets Breakdown (December 2025)
Orchestra BioMed Holdings Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.01% |
| Other Comprehensive Income | $60.00K | 0.09% |
| Other Components | $425.89 Million | 671.99% |
| Total Equity | $63.38 Million | 100.00% |
Orchestra BioMed Holdings Inc. Competitors by Market Cap
The table below lists competitors of Orchestra BioMed Holdings Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taiwan Paiho Ltd
TW:9938
|
$327.62 Million |
|
Symtek Automation Asia Co Ltd
TW:6438
|
$327.63 Million |
|
FLAT GLASS GROUP H YC-25
F:72T
|
$327.92 Million |
|
RCE Capital Berhad
KLSE:9296
|
$328.03 Million |
|
John Marshall Bancorp Inc
NASDAQ:JMSB
|
$327.40 Million |
|
Jiangsu Nanfang Medical
SHG:603880
|
$327.37 Million |
|
Aurora Cannabis Inc
TO:ACB
|
$327.31 Million |
|
ADTRAN Inc
NASDAQ:ADTN
|
$327.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Orchestra BioMed Holdings Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,958,000 to 63,378,000, a change of 30,420,000 (92.3%).
- Net loss of 52,701,000 reduced equity.
- New share issuances of 71,880,000 increased equity.
- Other comprehensive income increased equity by 8,000.
- Other factors increased equity by 11,233,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-52.70 Million | -83.15% |
| Share Issuances | $71.88 Million | +113.41% |
| Other Comprehensive Income | $8.00K | +0.01% |
| Other Changes | $11.23 Million | +17.72% |
| Total Change | $- | 92.30% |
Book Value vs Market Value Analysis
This analysis compares Orchestra BioMed Holdings Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-2.37 | $5.68 | x |
| 2021-12-31 | $-3.48 | $5.68 | x |
| 2022-12-31 | $2.06 | $5.68 | x |
| 2023-12-31 | $2.05 | $5.68 | x |
| 2024-12-31 | $0.90 | $5.68 | x |
| 2025-12-31 | $1.33 | $5.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Orchestra BioMed Holdings Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -83.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -157.40%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.81x
- Recent ROE (-83.15%) is below the historical average (-67.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -374.45% | 0.15x | 0.00x | $-16.50 Million |
| 2021 | 0.00% | 0.00% | -0.06x | 0.00x | $-15.89 Million |
| 2022 | -63.97% | -951.26% | 0.04x | 1.82x | $-38.86 Million |
| 2023 | -72.19% | -1779.71% | 0.03x | 1.40x | $-55.92 Million |
| 2024 | -185.16% | -2313.27% | 0.03x | 2.31x | $-64.32 Million |
| 2025 | -83.15% | -157.40% | 0.29x | 1.81x | $-59.04 Million |
Industry Comparison
This section compares Orchestra BioMed Holdings Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $122,747,735
- Average return on equity (ROE) among peers: -25.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Orchestra BioMed Holdings Inc. (OBIO) | $29.42 Million | 0.00% | 2.93x | $327.57 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $25.47 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $26.76 Million | -148.34% | 1.40x | $238.46 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $16.18 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $136.85 Million | -50.75% | 0.43x | $724.08 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $25.83 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.48 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $400.41 Million | -53.94% | 0.47x | $3.66 Billion |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more